Department of Psychiatry
Penn Behavioral Health

HIV/AIDS Prevention Research Division

subpage feature

HVTN 070


About the study

A Phase I clinical trial to evaluate the safety and immunogenicity of PENNVAX-B (gag, pol, env) given alone, with IL-12 DNA, or with a dose escalation of IL-15 DNA, in healthy, HIV-1 - uninfected adult participants.

Primary objectives:

To assess the safety and tolerability of a multigene HIV DNA vaccine (gag, pol, env) with or without co-administration of IL-12 DNA or IL-15 DNA in a cohort of HIV-uninfected healthy adults.
To evaluate the safety and tolerability of IL-15 DNA (escalating doses of 0.8 mg and 2 mg) with co-administration of 6 mg of a multigene HIV DNA vaccine (gag, pol, env).

 

Back to Current Studies

Connect with us twitter

Contact Us arrow

To make an appointment, or inquire further about our services, please call: 1-866-448-7366.

Click here for directions and contact information.